{
    "hands_on_practices": [
        {
            "introduction": "Accurately diagnosing and quantifying Acute Lymphoblastic Leukemia (ALL) is the first critical step in patient management. Flow cytometry is the cornerstone of this process, enabling clinicians to identify leukemic cells based on their unique size, granularity, and surface protein expression. This exercise  simulates a real-world diagnostic workflow, challenging you to apply a sequential \"gating\" strategy to isolate and quantify the malignant blast population from a complex bone marrow sample. Mastering this logical process is key to understanding how raw laboratory data is translated into a definitive blast percentage, a number fundamental to diagnosis and risk stratification.",
            "id": "4316990",
            "problem": "A bone marrow aspirate from a patient with suspected Acute Lymphoblastic Leukemia (ALL) is analyzed by flow cytometry. Flow cytometry quantifies individual cells by measuring light scatter and fluorescence. Forward scatter (FSC) approximates cell size and side scatter (SSC) approximates internal granularity. Acute lymphoblasts are typically characterized by low side scatter and dim expression of leukocyte common antigen (`CD45`), and B-lineage lymphoblasts commonly express cluster of differentiation 19 (`CD19`) and nuclear Terminal Deoxynucleotidyl Transferase (`TdT`). Intracellular TdT detection requires fixation and permeabilization, whereas viability assessment should precede fixation to avoid confounding dead-cell autofluorescence. \n\nStarting from these fundamentals, construct a scientifically justified gating strategy that:\n- excludes debris using the $ \\text{FSC} $ versus $ \\text{SSC} $ distribution,\n- removes doublets by $ \\text{FSC-A} $ versus $ \\text{FSC-H} $ singlet discrimination,\n- retains viable cells using a live/dead discriminator,\n- identifies blasts on a $ \\text{CD45} $ versus $ \\text{SSC} $ plot as the $ \\text{CD45}^{\\text{dim}}/\\text{SSC}^{\\text{low}} $ population, and\n- quantifies $ \\text{CD19}^{+}/\\text{TdT}^{+} $ events within the blast gate.\n\nYou are provided the following event counts at each sequential gate:\n- Total acquired events $ N_{\\text{acq}} = 5.0 \\times 10^{5} $,\n- After debris exclusion $ N_{\\text{cells}} = 4.8 \\times 10^{5} $,\n- After singlet discrimination $ N_{\\text{singlets}} = 4.5 \\times 10^{5} $,\n- After viability gating $ N_{\\text{viable}} = 4.2 \\times 10^{5} $,\n- Blasts identified on $ \\text{CD45} $ versus $ \\text{SSC} $: $ N_{\\text{blasts-gate}} = 5.04 \\times 10^{4} $,\n- Within the blast gate, $ \\text{CD19}^{+}/\\text{TdT}^{+} $ events: $ N_{\\text{CD19}^{+}\\text{/TdT}^{+}} = 4.032 \\times 10^{4} $.\n\nUsing a denominator that represents the total viable singlet nucleated cells in the sample, compute the fraction of $ \\text{CD19}^{+}/\\text{TdT}^{+} $ blasts in the marrow sample as a decimal number. Express your final answer as a single decimal value without a percent sign. No rounding is required.",
            "solution": "The problem requires the calculation of the fraction of $ \\text{CD19}^{+}/\\text{TdT}^{+} $ blasts in a bone marrow sample, based on sequential gating data from flow cytometry. The denominator for this fraction is specified as the \"total viable singlet nucleated cells\".\n\nFirst, a validation of the problem statement is performed.\n\n**Step 1: Extract Givens**\nThe provided data points are:\n- Total acquired events: $ N_{\\text{acq}} = 5.0 \\times 10^{5} $\n- Events after debris exclusion: $ N_{\\text{cells}} = 4.8 \\times 10^{5} $\n- Events after singlet discrimination: $ N_{\\text{singlets}} = 4.5 \\times 10^{5} $\n- Events after viability gating: $ N_{\\text{viable}} = 4.2 \\times 10^{5} $\n- Blasts identified in the $ \\text{CD45}^{\\text{dim}}/\\text{SSC}^{\\text{low}} $ gate: $ N_{\\text{blasts-gate}} = 5.04 \\times 10^{4} $\n- $ \\text{CD19}^{+}/\\text{TdT}^{+} $ events within the blast gate: $ N_{\\text{CD19}^{+}\\text{/TdT}^{+}} = 4.032 \\times 10^{4} $\n\nThe task is to compute a fraction where the numerator is the number of $ \\text{CD19}^{+}/\\text{TdT}^{+} $ blasts and the denominator is the count of \"total viable singlet nucleated cells\".\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, describing a standard flow cytometric analysis for Acute Lymphoblastic Leukemia (ALL). The markers ($ \\text{CD19} $, $ \\text{TdT} $, $ \\text{CD45} $), cell characteristics ($ \\text{CD45}^{\\text{dim}}/\\text{SSC}^{\\text{low}} $), and gating strategy (debris exclusion, doublet discrimination, viability gating) are all standard and correct within hematopathology. The data is self-contained and numerically consistent, with event counts decreasing at each successive gating step, as expected:\n$ N_{\\text{acq}} > N_{\\text{cells}} > N_{\\text{singlets}} > N_{\\text{viable}} > N_{\\text{blasts-gate}} > N_{\\text{CD19}^{+}\\text{/TdT}^{+}} $.\nSpecifically:\n$ 5.0 \\times 10^{5} > 4.8 \\times 10^{5} > 4.5 \\times 10^{5} > 4.2 \\times 10^{5} > 5.04 \\times 10^{4} > 4.032 \\times 10^{4} $.\nThe problem is well-posed, objective, and free of any flaws listed in the validation criteria.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A solution will be constructed.\n\n**Solution Derivation**\nThe goal is to compute the fraction $ F $, defined as:\n$$ F = \\frac{\\text{Number of } \\text{CD19}^{+}/\\text{TdT}^{+} \\text{ blasts}}{\\text{Number of total viable singlet nucleated cells}} $$\n\nThe numerator is the number of events corresponding to the specific leukemic blast population of interest. This is given as the count of $ \\text{CD19}^{+}/\\text{TdT}^{+} $ events within the blast gate.\n$$ \\text{Numerator} = N_{\\text{CD19}^{+}\\text{/TdT}^{+}} = 4.032 \\times 10^{4} $$\n\nThe denominator is the total population against which this subpopulation should be measured. The problem specifies this as the \"total viable singlet nucleated cells\". We can identify this population by following the described sequential gating strategy:\n1.  The initial acquisition yields $ N_{\\text{acq}} = 5.0 \\times 10^{5} $ total events.\n2.  Debris is excluded, leaving $ N_{\\text{cells}} = 4.8 \\times 10^{5} $ events, which represent the initial population of nucleated (and possibly non-nucleated) cells.\n3.  Doublets (cell clumps) are excluded, leaving $ N_{\\text{singlets}} = 4.5 \\times 10^{5} $ single cells.\n4.  Non-viable (dead) cells are excluded using a viability dye, leaving $ N_{\\text{viable}} = 4.2 \\times 10^{5} $ events.\n\nThis final count, $ N_{\\text{viable}} $, represents the population of cells that are single, viable, and nucleated (as the initial gate is designed to capture nucleated cells). Therefore, this is the correct denominator.\n$$ \\text{Denominator} = N_{\\text{viable}} = 4.2 \\times 10^{5} $$\n\nNow, we can compute the fraction $ F $:\n$$ F = \\frac{N_{\\text{CD19}^{+}\\text{/TdT}^{+}}}{N_{\\text{viable}}} = \\frac{4.032 \\times 10^{4}}{4.2 \\times 10^{5}} $$\n\nTo simplify the expression:\n$$ F = \\frac{4.032}{4.2 \\times 10^{1}} = \\frac{4.032}{42} $$\n\nPerforming the division:\n$$ F = 0.096 $$\n\nThis value represents the fraction of total viable singlet cells in the bone marrow sample that are identified as $ \\text{CD19}^{+}/\\text{TdT}^{+} $ leukemic blasts. The problem asks for this result as a single decimal value, which is $ 0.096 $.",
            "answer": "$$\\boxed{0.096}$$"
        },
        {
            "introduction": "Staging the disease, particularly assessing its spread to the Central Nervous System (CNS), is a vital step that dictates the intensity of therapy. This assessment relies on analyzing the cerebrospinal fluid (CSF), but the procedure can be confounded by accidental blood contamination, known as a \"traumatic tap.\" This practice  presents a common clinical dilemma and equips you with the standard mathematical tool to resolve it. By applying a correction formula based on red blood cell ratios, you will learn to adjust the observed cell counts to determine the true underlying CNS status, demonstrating how quantitative reasoning is essential for accurate clinical decision-making in the face of imperfect data.",
            "id": "5094624",
            "problem": "A child with newly diagnosed Acute Lymphoblastic Leukemia (ALL) undergoes a diagnostic lumbar puncture complicated by a traumatic tap. In pediatric ALL, central nervous system (CNS) status is determined using cerebrospinal fluid (CSF) cell counts and cytospin findings, and traumatic blood contamination requires adjustment to estimate the true CSF white blood cell (WBC) and blast burden. Consider the following measured values:\n\n- Peripheral blood red blood cell (RBC) concentration $R_{\\mathrm{PB}} = 4.8 \\times 10^{6}$ cells per microliter.\n- Peripheral blood white blood cell concentration $W_{\\mathrm{PB}} = 18{,}000$ cells per microliter.\n- Peripheral blood blast fraction $f_{\\mathrm{PB}} = 0.70$ (expressed as a decimal).\n- CSF RBC count $R_{\\mathrm{CSF}} = 6{,}000$ cells per microliter.\n- Observed CSF WBC count $W_{\\mathrm{CSF,obs}} = 28$ cells per microliter.\n- Observed CSF blast count on CSF cytospin $B_{\\mathrm{CSF,obs}} = 20$ cells per microliter.\n\nUse the following well-tested contamination correction principle: in a traumatic tap, the fraction of blood admixed into CSF can be approximated by the ratio of CSF RBCs to peripheral blood RBCs, namely $p = R_{\\mathrm{CSF}} / R_{\\mathrm{PB}}$. Under the mixture assumption that the admixed blood contributes WBCs and blasts in proportion to peripheral blood composition, the expected contamination WBCs in CSF are $W_{\\mathrm{cont}} = p \\cdot W_{\\mathrm{PB}}$, and the expected contamination blasts are $B_{\\mathrm{cont}} = p \\cdot W_{\\mathrm{PB}} \\cdot f_{\\mathrm{PB}}$. The corrected CSF WBC count and corrected CSF blast count are then $W_{\\mathrm{corr}} = W_{\\mathrm{CSF,obs}} - W_{\\mathrm{cont}}$ and $B_{\\mathrm{corr}} = B_{\\mathrm{CSF,obs}} - B_{\\mathrm{cont}}$, respectively. The adjusted CSF blast fraction is $f_{\\mathrm{CSF,corr}} = B_{\\mathrm{corr}} / W_{\\mathrm{corr}}$ (expressed as a decimal, not a percent).\n\nUsing these corrections, determine the CNS status according to the following definitions applied to corrected values: CNS1 if $W_{\\mathrm{corr}} < 5$ and $B_{\\mathrm{corr}} = 0$; CNS2 if $W_{\\mathrm{corr}} < 5$ and $B_{\\mathrm{corr}} > 0$; CNS3 if $W_{\\mathrm{corr}} \\geq 5$ and $B_{\\mathrm{corr}} > 0$. Let the numeric CNS code be $S \\in \\{1,2,3\\}$ corresponding to CNS1, CNS2, CNS3, respectively.\n\nCompute the adjusted CSF blast fraction $f_{\\mathrm{CSF,corr}}$ and determine $S$. Report as your final numeric output the product $P = f_{\\mathrm{CSF,corr}} \\cdot S$. Round your final numeric output to four significant figures. Do not include any units in your final numeric output.",
            "solution": "The problem requires the calculation of a product $P = f_{\\mathrm{CSF,corr}} \\cdot S$, where $f_{\\mathrm{CSF,corr}}$ is the adjusted cerebrospinal fluid (CSF) blast fraction and $S$ is a numeric code representing the central nervous system (CNS) status. The calculation must correct for peripheral blood contamination in a CSF sample obtained via a traumatic lumbar puncture.\n\nThe given data are:\n- Peripheral blood red blood cell (RBC) concentration: $R_{\\mathrm{PB}} = 4.8 \\times 10^{6}$ cells/µL\n- Peripheral blood white blood cell (WBC) concentration: $W_{\\mathrm{PB}} = 18{,}000$ cells/µL, which is $1.8 \\times 10^{4}$ cells/µL\n- Peripheral blood blast fraction: $f_{\\mathrm{PB}} = 0.70$\n- CSF RBC count: $R_{\\mathrm{CSF}} = 6{,}000$ cells/µL, which is $6.0 \\times 10^{3}$ cells/µL\n- Observed CSF WBC count: $W_{\\mathrm{CSF,obs}} = 28$ cells/µL\n- Observed CSF blast count: $B_{\\mathrm{CSF,obs}} = 20$ cells/µL\n\nThe solution follows the sequence of calculations defined in the problem statement.\n\nFirst, we calculate the fraction of peripheral blood admixed into the CSF, denoted by $p$. This is given by the ratio of the CSF RBC count to the peripheral blood RBC concentration.\n$$p = \\frac{R_{\\mathrm{CSF}}}{R_{\\mathrm{PB}}} = \\frac{6.0 \\times 10^{3}}{4.8 \\times 10^{6}} = \\frac{6.0}{4.8} \\times 10^{3-6} = 1.25 \\times 10^{-3}$$\n\nNext, we calculate the concentrations of WBCs and blasts contributed to the CSF sample by this blood contamination.\nThe contaminating WBC concentration, $W_{\\mathrm{cont}}$, is calculated as:\n$$W_{\\mathrm{cont}} = p \\cdot W_{\\mathrm{PB}} = (1.25 \\times 10^{-3}) \\cdot (1.8 \\times 10^{4}) = 2.25 \\times 10^{1} = 22.5$$\nThe contaminating blast concentration, $B_{\\mathrm{cont}}$, is calculated as:\n$$B_{\\mathrm{cont}} = p \\cdot W_{\\mathrm{PB}} \\cdot f_{\\mathrm{PB}} = W_{\\mathrm{cont}} \\cdot f_{\\mathrm{PB}} = 22.5 \\cdot 0.70 = 15.75$$\nThe units for these concentrations are cells/µL.\n\nNow, we can determine the corrected (true) CSF WBC and blast counts by subtracting the contamination component from the observed counts.\nThe corrected CSF WBC count, $W_{\\mathrm{corr}}$, is:\n$$W_{\\mathrm{corr}} = W_{\\mathrm{CSF,obs}} - W_{\\mathrm{cont}} = 28 - 22.5 = 5.5$$\nThe corrected CSF blast count, $B_{\\mathrm{corr}}$, is:\n$$B_{\\mathrm{corr}} = B_{\\mathrm{CSF,obs}} - B_{\\mathrm{cont}} = 20 - 15.75 = 4.25$$\nThe units for these corrected counts are also cells/µL.\n\nWith the corrected counts, we determine the CNS status according to the given definitions:\n- CNS1: $W_{\\mathrm{corr}} < 5$ and $B_{\\mathrm{corr}} = 0$\n- CNS2: $W_{\\mathrm{corr}} < 5$ and $B_{\\mathrm{corr}} > 0$\n- CNS3: $W_{\\mathrm{corr}} \\geq 5$ and $B_{\\mathrm{corr}} > 0$\n\nOur calculated values are $W_{\\mathrm{corr}} = 5.5$ and $B_{\\mathrm{corr}} = 4.25$. Since $5.5 \\geq 5$ and $4.25 > 0$, the conditions for CNS3 are met. Therefore, the CNS status is CNS3, and the corresponding numeric code is $S=3$.\n\nThe next step is to calculate the adjusted CSF blast fraction, $f_{\\mathrm{CSF,corr}}$, defined as the ratio of the corrected blast count to the corrected WBC count.\n$$f_{\\mathrm{CSF,corr}} = \\frac{B_{\\mathrm{corr}}}{W_{\\mathrm{corr}}} = \\frac{4.25}{5.5} = \\frac{17}{22}$$\n\nFinally, we compute the required product, $P = f_{\\mathrm{CSF,corr}} \\cdot S$.\n$$P = \\left(\\frac{17}{22}\\right) \\cdot 3 = \\frac{51}{22}$$\nTo obtain the numerical value, we perform the division:\n$$P \\approx 2.3181818...$$\n\nThe problem requires rounding the final numeric output to four significant figures. The fifth significant digit is $1$, so we round down.\n$$P \\approx 2.318$$",
            "answer": "$$\\boxed{2.318}$$"
        },
        {
            "introduction": "Beyond diagnosis and staging, the future of oncology lies in using quantitative models to predict treatment response and guide personalized therapy. Minimal Residual Disease (MRD) kinetics—the rate at which cancer cells are cleared—provides a powerful predictive biomarker. This advanced exercise  elevates your skills from data interpretation to predictive modeling, using principles of survival analysis and exponential decay to compare the long-term, risk-benefit balance of two major treatment strategies: chemotherapy versus allogeneic transplantation. By navigating the competing risks of relapse and treatment-related mortality, you will engage in the sophisticated quantitative reasoning that underpins modern, evidence-based therapeutic decisions.",
            "id": "4316974",
            "problem": "A patient with Acute Lymphoblastic Leukemia (ALL) has end-of-induction Minimal Residual Disease (MRD) of $5 \\times 10^{-4}$, measured as the fraction of leukemic cells among nucleated bone marrow cells. You will compare two post-induction strategies: continued chemotherapy and early Allogeneic Hematopoietic Cell Transplantation (allo-HCT). The risk-benefit metric is defined as the difference in $3$-year leukemia-free survival between the allo-HCT strategy and the chemotherapy-only strategy.\n\nUse the following scientifically grounded modeling assumptions and parameters:\n\n1. Minimal Residual Disease (MRD) decays exponentially under ongoing therapy, so that for time $t$ (in years) after the end of induction, the MRD burden is $B(t) = B_{0} \\exp(-\\delta t)$, where $B_{0} = 5 \\times 10^{-4}$ is the baseline MRD at the end of induction, and $\\delta$ is a positive constant that encodes treatment-driven clearance kinetics.\n\n2. Under chemotherapy alone, the instantaneous relapse hazard at time $t$ is proportional to the current MRD burden, $h_{c}(t) = k_{c} B(t)$, where $k_{c}$ is a positive constant.\n\n3. Under allo-HCT, two processes contribute to events:\n   - Early Non-Relapse Mortality (NRM) with a constant hazard $h_{\\mathrm{NRM}}(t) = \\mu$ over $t \\in [0, \\tau]$ and $h_{\\mathrm{NRM}}(t) = 0$ for $t > \\tau$.\n   - Post-transplant relapse with hazard $h_{t}(t) = k_{t} \\tilde{B}(t)$, where the effective MRD $\\tilde{B}(t)$ is reduced at $t=0$ by a factor $r$ due to cytoreduction and graft-versus-leukemia effects, and then decays exponentially: $\\tilde{B}(t) = r B_{0} \\exp(-\\delta_{t} t)$.\n\n4. Survival analysis is based on standard definitions: the cause-specific hazard functions integrate to give the cumulative hazard over an interval, and the survival function over that interval is the exponential of the negative cumulative hazard. When multiple independent causes act additively on hazards, the combined survival is the exponential of the negative integral of the sum of hazards.\n\nParameter values:\n- Chemotherapy kinetics: $\\delta = 1.5 \\,\\mathrm{year}^{-1}$ and $k_{c} = 1000 \\,\\mathrm{year}^{-1}$.\n- Transplant kinetics: $r = 0.1$, $\\delta_{t} = 2.0 \\,\\mathrm{year}^{-1}$, and $k_{t} = 1000 \\,\\mathrm{year}^{-1}$.\n- Non-Relapse Mortality (NRM): $\\mu = 0.5 \\,\\mathrm{year}^{-1}$ acting over $\\tau = 0.25 \\,\\mathrm{year}$.\n\nLet $T = 3$ be the $3$-year horizon. Compute the risk-benefit metric\n$$\n\\Delta = S_{\\mathrm{allo\\text{-}HCT}}(T) - S_{\\mathrm{chemo}}(T),\n$$\nwhere $S_{\\mathrm{chemo}}(T)$ is the $3$-year relapse-free survival under chemotherapy (ignoring non-relapse mortality during chemotherapy), and $S_{\\mathrm{allo\\text{-}HCT}}(T)$ is the $3$-year leukemia-free survival under allo-HCT accounting for both NRM and relapse. Round your final answer to four significant figures and express it as a decimal fraction with no unit and no percentage sign.",
            "solution": "The problem statement has been analyzed and is deemed valid. It is scientifically grounded, self-contained, and well-posed. The problem provides a clear mathematical model based on established principles of survival analysis and population dynamics in oncology. All necessary parameters and definitions are provided to compute a unique solution.\n\nThe task is to compute the risk-benefit metric $\\Delta = S_{\\mathrm{allo\\text{-}HCT}}(T) - S_{\\mathrm{chemo}}(T)$ at a time horizon of $T = 3$ years. This requires the calculation of the $3$-year leukemia-free survival probability for two different therapeutic strategies: chemotherapy alone and allogeneic hematopoietic cell transplantation (allo-HCT).\n\nFirst, we calculate the survival probability for the chemotherapy-only strategy, $S_{\\mathrm{chemo}}(T)$. The survival function is given by $S(T) = \\exp(-H(T))$, where $H(T)$ is the cumulative hazard, $H(T) = \\int_0^T h(t) dt$.\n\nFor the chemotherapy strategy, the instantaneous relapse hazard is $h_{c}(t) = k_{c} B(t)$. The MRD burden $B(t)$ decays according to $B(t) = B_{0} \\exp(-\\delta t)$. Therefore, the hazard function is:\n$$\nh_{c}(t) = k_{c} B_{0} \\exp(-\\delta t)\n$$\nThe cumulative hazard for relapse under chemotherapy, $H_{c}(T)$, is the integral of the hazard function from $t=0$ to $t=T$:\n$$\nH_{c}(T) = \\int_{0}^{T} h_{c}(t) dt = \\int_{0}^{T} k_{c} B_{0} \\exp(-\\delta t) dt\n$$\n$$\nH_{c}(T) = k_{c} B_{0} \\left[ -\\frac{1}{\\delta} \\exp(-\\delta t) \\right]_{0}^{T} = k_{c} B_{0} \\left( -\\frac{1}{\\delta} \\exp(-\\delta T) - \\left(-\\frac{1}{\\delta} \\exp(0)\\right) \\right)\n$$\n$$\nH_{c}(T) = \\frac{k_{c} B_{0}}{\\delta} (1 - \\exp(-\\delta T))\n$$\nThe survival probability under chemotherapy is then:\n$$\nS_{\\mathrm{chemo}}(T) = \\exp(-H_{c}(T)) = \\exp\\left(-\\frac{k_{c} B_{0}}{\\delta} (1 - \\exp(-\\delta T))\\right)\n$$\n\nNext, we calculate the survival probability for the allo-HCT strategy, $S_{\\mathrm{allo\\text{-}HCT}}(T)$. This strategy involves two competing risks: relapse and non-relapse mortality (NRM). The total hazard, $h_{\\mathrm{total}}(t)$, is the sum of the cause-specific hazards: $h_{\\mathrm{total}}(t) = h_{t}(t) + h_{\\mathrm{NRM}}(t)$.\n\nThe relapse hazard is $h_{t}(t) = k_{t} \\tilde{B}(t)$, with the effective MRD burden being $\\tilde{B}(t) = r B_{0} \\exp(-\\delta_{t} t)$. Thus:\n$$\nh_{t}(t) = k_{t} r B_{0} \\exp(-\\delta_{t} t)\n$$\nThe NRM hazard is a piecewise constant function: $h_{\\mathrm{NRM}}(t) = \\mu$ for $t \\in [0, \\tau]$ and $h_{\\mathrm{NRM}}(t) = 0$ for $t > \\tau$.\n\nThe total cumulative hazard, $H_{\\mathrm{total}}(T)$, is the integral of the total hazard. Since $T > \\tau$, we must split the integral:\n$$\nH_{\\mathrm{total}}(T) = \\int_{0}^{T} h_{\\mathrm{total}}(t) dt = \\int_{0}^{T} (h_{t}(t) + h_{\\mathrm{NRM}}(t)) dt\n$$\n$$\nH_{\\mathrm{total}}(T) = \\int_{0}^{T} h_{t}(t) dt + \\int_{0}^{T} h_{\\mathrm{NRM}}(t) dt\n$$\nThe cumulative hazard from relapse, $H_t(T)$, is:\n$$\nH_{t}(T) = \\int_{0}^{T} k_{t} r B_{0} \\exp(-\\delta_{t} t) dt = \\frac{k_{t} r B_{0}}{\\delta_{t}} (1 - \\exp(-\\delta_{t} T))\n$$\nThe cumulative hazard from NRM, $H_{\\mathrm{NRM}}(T)$, is:\n$$\nH_{\\mathrm{NRM}}(T) = \\int_{0}^{\\tau} \\mu dt + \\int_{\\tau}^{T} 0 dt = \\mu \\tau\n$$\nThe total cumulative hazard for allo-HCT is the sum:\n$$\nH_{\\mathrm{total}}(T) = H_{t}(T) + H_{\\mathrm{NRM}}(T) = \\frac{k_{t} r B_{0}}{\\delta_{t}} (1 - \\exp(-\\delta_{t} T)) + \\mu \\tau\n$$\nThe survival probability under allo-HCT is:\n$$\nS_{\\mathrm{allo\\text{-}HCT}}(T) = \\exp(-H_{\\mathrm{total}}(T)) = \\exp\\left( -\\left[ \\frac{k_{t} r B_{0}}{\\delta_{t}} (1 - \\exp(-\\delta_{t} T)) + \\mu \\tau \\right] \\right)\n$$\n\nNow, we substitute the given parameter values:\n$B_{0} = 5 \\times 10^{-4}$, $T = 3$,\n$\\delta = 1.5$, $k_{c} = 1000$,\n$r = 0.1$, $\\delta_{t} = 2.0$, $k_{t} = 1000$,\n$\\mu = 0.5$, $\\tau = 0.25$.\nAll time-related parameters are in units of years or inverse years.\n\nCalculating $S_{\\mathrm{chemo}}(3)$:\n$$\nH_{c}(3) = \\frac{1000 \\times (5 \\times 10^{-4})}{1.5} (1 - \\exp(-1.5 \\times 3)) = \\frac{0.5}{1.5} (1 - \\exp(-4.5)) = \\frac{1}{3} (1 - \\exp(-4.5))\n$$\n$H_{c}(3) \\approx \\frac{1}{3} (1 - 0.011109) = 0.329630$\n$$\nS_{\\mathrm{chemo}}(3) = \\exp(-H_{c}(3)) \\approx \\exp(-0.329630) \\approx 0.719211\n$$\n\nCalculating $S_{\\mathrm{allo\\text{-}HCT}}(3)$:\nThe cumulative hazard from relapse is:\n$$\nH_t(3) = \\frac{1000 \\times 0.1 \\times (5 \\times 10^{-4})}{2.0} (1 - \\exp(-2.0 \\times 3)) = \\frac{0.05}{2.0} (1 - \\exp(-6)) = 0.025 (1 - \\exp(-6))\n$$\n$H_t(3) \\approx 0.025 (1 - 0.002479) = 0.024938$\nThe cumulative hazard from NRM is:\n$$\nH_{\\mathrm{NRM}}(3) = 0.5 \\times 0.25 = 0.125\n$$\nThe total cumulative hazard is:\n$$\nH_{\\mathrm{total}}(3) = H_t(3) + H_{\\mathrm{NRM}}(3) \\approx 0.024938 + 0.125 = 0.149938\n$$\nThe survival probability is:\n$$\nS_{\\mathrm{allo\\text{-}HCT}}(3) = \\exp(-H_{\\mathrm{total}}(3)) \\approx \\exp(-0.149938) \\approx 0.860765\n$$\n\nFinally, we compute the risk-benefit metric $\\Delta$:\n$$\n\\Delta = S_{\\mathrm{allo\\text{-}HCT}}(3) - S_{\\mathrm{chemo}}(3)\n$$\n$$\n\\Delta \\approx 0.860765 - 0.719211 = 0.141554\n$$\nThe problem requires the answer to be rounded to four significant figures. The first four significant figures are $1, 4, 1, 5$. The fifth digit is $5$, so we round up the fourth digit.\n$$\n\\Delta \\approx 0.1416\n$$\nThe positive value of $\\Delta$ indicates that, under this model, the allo-HCT strategy offers a higher $3$-year leukemia-free survival probability compared to the chemotherapy-only strategy for a patient with this specific risk profile.",
            "answer": "$$\\boxed{0.1416}$$"
        }
    ]
}